Journal of Allergy and Clinical Immunology
Particle size of inhaled corticosteroids: Does it matter?
Section snippets
Particle size and delivery device differences of inhaled corticosteroids
Asthma is known to be a disease of the entire respiratory tract, including the large, intermediate, and small airways. It has been clearly shown that inflammation, obstruction, and remodeling occur throughout the respiratory tract.1 This is true for mild, moderate, and severe asthma, and although the severity can change with the classification of asthma, processes like inflammation occur in small airways, even in subjects with mild asthma.2 It is of importance to note that natural allergens,
ICS therapy: small versus large particles
Although ICSs are effective for the treatment of asthma, unfortunately, regular use of ICSs will not ensure total control of the disease in all patients.17 Furthermore, ICS use has been associated with a variety of systemic and upper airway side effects that limit regular use.18 Improving the clinical efficacy and decreasing the safety concerns of ICSs would be an extremely useful step in enabling more effective asthma control. There are 2 possible ways to improve the risk/benefit profile of
Pharmacoeconomics of particle size
The National Asthma Education and Prevention Program Expert Panel Report 3 and Global Initiative for Asthma guidelines and the US Food and Drug Administration recommendations favoring ICS monotherapy to initiate treatment in patients with persistent asthma are based on an evidence-based evaluation of a large body of clinical data using clinical and physiologic outcomes. Several pharmacoeconomic analyses support the validity of this approach and raise economic concerns about unnecessary
References (50)
- et al.
Inflammation of small airways in asthma
J Allergy Clin Immunol
(1997) - et al.
Airways remodeling is a distinctive feature of asthma and is related to severity of disease
Chest
(1997) - et al.
Release of allergens as respirable aerosols: a link between grass pollen and asthma
J Allergy Clin Immunol
(2002) - et al.
Subpollen particles: carriers of allergenic proteins and oxidases
J Allergy Clin Immunol
(2006) Improved delivery of inhaled steroids to the large and small airways
Respir Med
(1998)- et al.
A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers
Int J Pharm
(1999) - et al.
Inhaled corticosteroids: past lessons and future issues
J Allergy Clin Immunol
(2003) - et al.
A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial
J Allergy Clin Immunol
(1992) - et al.
Epithelial-mesenchymal interactions in the pathogenesis of asthma
J Allergy Clin Immunol
(2000) - et al.
Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma
Chest
(1999)
Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
Respir Med
Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate
Chest
Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant
J Allergy Clin Immunol
Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients
Ann Allergy Asthma Immunol
The relative clinical effectiveness of HFA-BDP and fluticasone propionate in asthma
Respir Med
Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma
Respir Med
The functional benefit of anti-inflammatory aerosols in the lung periphery
J Allergy Clin Immunol
Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry
Pulm Pharmacol Ther
Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol
Respir Med
Prescribing of fluticasone propionate/salmeterol combinations as initial therapy for patients with asthma in a commercially-insured population
J Allergy Clin Immunol
Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy
Respir Med
Glucocorticoid receptor localization in normal and asthmatic lung
Am J Respir Crit Care Med
Targeting inhaled steroids
Int J Clin Pract Suppl
Relevance of radiolabeled steroid inhalation studies to clinical outcomes
J Aerosol Med
Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
Eur Respir J
Cited by (0)
Supported by an unrestricted grant from Teva Respiratory, LLC.
Disclosure of potential conflict of interest: C. Leach is a consultant for Teva Pharmaceuticals. G. L. Colice is a speaker, consultant, and board member of GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Lilly, Almirall Forest, and Teva Pharmaceuticals; has provided expert witness testimony on a patent on nebulized budesonide; and has had numerous dealings with the American College of Chest Physicians. A. Luskin is the owner of Healthy Airways; is a consultant for Merck, Genentech, and Meda; has received research support from Genentech/Novartis; and has consulted for AstraZeneca, Schering-Plough, and SRxA.
Reprint requests: Richard J. Martin, MD, National Jewish Health, 1400 Jackson St, Denver, CO 80206. E-mail: [email protected].